Sector News

UCB reveals new Bimzelx ‘complete skin clearance’ data

September 11, 2022
Life sciences

UCB has announced new three-year results from the BE BRIGHT open-label extension study evaluating the long-term safety, tolerability and efficacy of Bimzelx – also known bimekizumab – in adults with moderate to severe plaque psoriasis who completed one of three pivotal phase 3 studies.

This data, together with a three-year safety analysis of pooled data from phase 2 and 3 studies, is being presented at the European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, over the next few days. A total of eleven abstracts highlighting data related to bimekizumab in psoriasis are being presented at the congress.

Bimekizumab is the first selective IL-17A and IL-17F inhibitor to be approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Data presented from the BE BRIGHT study showed that over eight out of ten patients who achieved complete skin clearance (PASI 100) – following 16 weeks of bimekizumab treatment – maintained PASI 100 response and health-related quality of life outcomes for three years with continuous maintenance dosing.

Pooled data from up to three years of treatment in phase 2 and 3 clinical trials showed that bimekizumab was generally well-tolerated over this period with no safety signals identified.

“These positive results highlight the deep and long-lasting skin clearance achieved with bimekizumab, along with a consistent safety and tolerability profile, and reinforce the positive relationship clearing skin has on patients’ quality of life. This new data adds to the growing body of evidence supporting longer-term use of bimekizumab in moderate-to-severe plaque psoriasis,” reflected Emmanuel Caeymaex, executive vice president, immunology solutions at UCB.

“The findings presented today show that bimekizumab provided maintenance of completely clear skin and health-related quality of life outcomes in the majority of patients with moderate-to-severe plaque psoriasis over a three-year period,” concluded Dr Bruce Strober, clinical Professor of dermatology at Yale University.

“The goal of psoriasis treatment often is complete clearance of skin symptoms and the availability of long-term data across treatment options is important since it supports healthcare providers and patients to be more informed when making treatment decisions,” he added.

by John Pinching

Source: pharmatimes.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach